Martin Capital Advisors LLP Acquires 267 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Martin Capital Advisors LLP boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,679 shares of the medical equipment provider’s stock after purchasing an additional 267 shares during the quarter. Martin Capital Advisors LLP’s holdings in Lantheus were worth $724,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. Knights of Columbus Asset Advisors LLC increased its stake in Lantheus by 125.6% in the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 46,804 shares of the medical equipment provider’s stock worth $2,902,000 after acquiring an additional 26,059 shares during the last quarter. Avior Wealth Management LLC increased its stake in Lantheus by 5.6% in the 4th quarter. Avior Wealth Management LLC now owns 5,858 shares of the medical equipment provider’s stock worth $363,000 after acquiring an additional 309 shares during the last quarter. Strs Ohio increased its stake in Lantheus by 12.1% in the 4th quarter. Strs Ohio now owns 7,400 shares of the medical equipment provider’s stock worth $458,000 after acquiring an additional 800 shares during the last quarter. Phocas Financial Corp. increased its stake in Lantheus by 1.8% in the 4th quarter. Phocas Financial Corp. now owns 93,187 shares of the medical equipment provider’s stock worth $5,778,000 after acquiring an additional 1,666 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in Lantheus in the 4th quarter worth approximately $1,190,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 2.4 %

Shares of LNTH stock traded up $1.48 during mid-day trading on Friday, hitting $63.81. The stock had a trading volume of 798,117 shares, compared to its average volume of 1,059,004. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $100.85. The firm has a market capitalization of $4.37 billion, a P/E ratio of 13.59 and a beta of 0.53. The firm’s 50-day moving average is $60.66 and its two-hundred day moving average is $62.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. On average, analysts predict that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of a number of research reports. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial reiterated a “buy” rating and issued a $82.00 target price (up previously from $80.00) on shares of Lantheus in a report on Monday, February 26th. Finally, B. Riley lifted their target price on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $104.71.

Insider Transactions at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. In the last three months, insiders sold 94,545 shares of company stock valued at $6,169,936. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.